Skip to main content
Signal8
Launch Terminal

PolyPid Ltd. (PYPD)

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Biotechnology

PolyPid Ltd. logo

PolyPid Ltd.

NASDAQ:PYPDHealthcare
-3.58%$5.39
AH$5.45+1.11%vs close
Mkt Cap$112.46M
Float15.52M
O/S20.86M
Vol
$ Vol
RVOL
Inst Own15.8%
SI1.4%
Earnings
Dilution
PolyPid Ltd. logoNASDAQ:PYPD$5.39-3.58%
Phase Distribution
7 lead-sponsored trials·0 active·6 completed
Phase 1/21
Phase 21
Phase 33
Not applicable2
Status Overview
Completed6
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Terminated

    D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

    D-PLEX

    Surgical Site Infection, Sternal Infection +1

    Enrollment
    2
    Start
    Dec 2019
    Primary Completion
    Oct 2022
    Completion
    Oct 2022
    NCT03558984
  • Phase 3
    Completed

    D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

    D-PLEX, Standard of Care (SoC)

    Surgical Site Infection, Colon Surgery +2

    Enrollment
    977
    Start
    Jun 2020
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT04233424
  • Phase 3
    Completed

    D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

    D-PLEX

    Surgical Site Infection, Colon Surgery +2

    Enrollment
    975
    Start
    Dec 2020
    Primary Completion
    Apr 2025
    Completion
    May 2025
    NCT04411199
  • Phase 2
    Completed

    D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

    D-PLEX

    Abdominal Surgery, Colon Surgery +1

    Enrollment
    202
    Start
    Oct 2018
    Primary Completion
    Sep 2019
    Completion
    Oct 2019
    NCT03633123
  • Phase 1/2
    Completed

    Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery.

    D-PLEX

    Postoperative Wound Infection Superficial Incisional, Postoperative Wound Infection Deep Incisional Surgical Site

    Enrollment
    81
    Start
    Oct 2016
    Primary Completion
    Feb 2018
    Completion
    May 2018
    NCT02731573
  • Not applicable
    Completed

    Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures

    BonyPid-1000, Standard of Care (SOC) treatment

    Tibial Fractures, Open Fractures

    Enrollment
    51
    Start
    Oct 2015
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT02491047
  • Not applicable
    Completed

    BonyPid-500TM Bone Graft Substitute Study

    BonyPid 500TM implantation concomitantly to SOC treatment, SOC treatment only

    Peri Implantitis

    Enrollment
    27
    Start
    Mar 2016
    Primary Completion
    May 2018
    Completion
    Jun 2018
    NCT02531100
Search ClinicalTrials.gov for “PolyPid”